PET scan study for heart scarring in heart failure
Part of Heart & circulation clinical trials.
This study uses a special PET scan to look for scarring (fibrosis) in the heart muscle of people with heart failure. It may help doctors better understand why some hearts get stiff or weak.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have heart failure with either normal pumping function (ejection fraction 50% or higher) or reduced pumping function (ejection fraction 40% or lower).
- You have had an echocardiogram (ultrasound of the heart) in the last 3 months.
- You have had a cardiac MRI in the last 3 months.
- You have had a normal coronary angiogram or CT scan of the heart arteries within the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how heart scarring after a major heart attack affects the heart's shape and function. It might help people who developed a bulge (aneurysm) in the heart wall after their attack.
This study uses two imaging scans to see if parts of your heart muscle are still alive but not working well. This could help doctors decide if you might benefit from heart bypass surgery.
This study uses advanced imaging (PET/MR or PET/CT) to look at scarring (fibrosis) in the heart muscle. It is for people with various heart muscle diseases, including heart failure with preserved pumping, thickened heart muscle, high blood pressure-related heart damage, heart inflammation, and others.
This study uses a special PET scan (68Ga-FAPI) to look at inflammation in the heart. It may help researchers understand heart failure and cardiac sarcoidosis better.
This trial is testing a new imaging method (68Ga-FAPI PET/CMR) to better see and understand heart problems. It might help doctors diagnose or monitor conditions like heart failure or inflammation.
This study uses a special imaging agent to see a protein called PDGFRß in the heart, which may help detect scarring (fibrosis) after a heart attack or in heart failure. It aims to improve how we understand and treat heart muscle damage.
Hear when a new Myocardial Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.